Apoquel launched in 2013 and rapidly became a companion animal blockbuster. By 2025, it was generating over a billion dollars annually, but that premium had accumulated a real cost. List price pressure was mounting, and prescribers in independent practices were increasingly sensitized to it.

Zenrelia didn't win because Apoquel was weak. It won because Apoquel had done the category-building work, and Zenrelia entered at the moment when that category was ripe for a credible, affordable alternative. The switching audience was already motivated before the first sales call.

Most launch teams think about timing in regulatory terms. Zenrelia's team thought about it in market psychology terms, and the distinction made all the difference.

In a mature, proven category, price sensitivity shifts over time. Apoquel had earned premium positioning through a decade of clinical evidence and prescriber loyalty. But that premium had become a real friction point in independent practices serving cost-conscious pet owners.

Zenrelia chose affordability as the lead commercial message in price-sensitive geographies. This wasn't a concession on product value; it was a strategic decision to maximize market penetration velocity over near-term margin in those specific markets.

The execution required segmenting practices by price sensitivity and running genuinely different conversations. Where cost drove the decision, price led. Where clinical differentiation drove the decision, efficacy led.

The traditional pharmaceutical launch model sequences markets: file in the US, launch in the US, then begin the international cascade 18–36 months later. By the time Europe or Japan sees the product, the US data package is mature, but so is the competitive response.

Zenrelia collapsed that timeline. Eight regulatory approvals in 18 months across North America, South America, Europe, and Asia-Pacific. Each market launched with full commercial teams and full formulary ambition, not a phased rollout watching the US test first.

Brazil, Canada, Japan, and key EU markets all hit multi-year analog share benchmarks in Year 1. The global commercial organization learned together, refined messaging together, and built momentum no sequential launch could have generated.

The companion animal industry has consolidated rapidly. Consolidator-owned practices now represent a significant and growing share of total prescribing volume. A win at the corporate level is qualitatively different from any number of independent clinic wins.

Early formulary placement with corporate accounts gave Zenrelia's commercial team a volume foundation that independent rep coverage alone could not have built. The field force reinforced the corporate account strategy rather than being asked to create volume from scratch.

Corporate accounts provide leverage, and that leverage needs to be established before launch, not after you've exhausted the independent call cycle.

Elanco's Costco and Dollar General partnerships signal a strategic shift: the companion animal prescription ecosystem is increasingly shaped by retail demand signals. Pet owners don't only follow vet recommendations; they arrive at appointments having already encountered the brand.

OTC products create brand familiarity that translates into receptivity when a vet recommends a prescription product from the same manufacturer. The DTC strategy isn't a separate P&L; it's a demand signal that makes every field rep conversation shorter and warmer.

A pet owner who recognizes the brand from a Costco shelf is already predisposed to say yes when a vet mentions Zenrelia. That predisposition doesn't show up in the rep's call data.